Essential Information for Capricor Therapeutics Investors
Attention shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR): there are critical developments regarding potential class action rights that warrant your attention. If you acquired shares of CAPR during the defined class period, it is vital to explore your options for recovery.
Class Action Overview and Shareholder Encouragement
The Gross Law Firm has reached out to shareholders encouraging them to contact them to discuss possible lead plaintiff appointments. Remember, becoming a lead plaintiff is not a requisite to be part of the recovery.
Notification of the Class Period
CLASS PERIOD: October 9, 2024, to July 10, 2025. Shareholders who purchased during this timeframe are urged to reach out and ensure their rights are protected.
Key Allegations Against Capricor Therapeutics
The ongoing lawsuit includes serious allegations claiming that Capricor Therapeutics provided misleading information regarding its lead cell therapy candidate, deramiocel, intended for treating cardiomyopathy linked with Duchenne muscular dystrophy (DMD). While conveying optimistic projections about obtaining a Biologics License Application (BLA) from the U.S. FDA, the company allegedly obscured critical safety and efficacy data from its Phase 2 HOPE-2 trial.
Impact of FDA's Complete Response Letter
Capricor received a Complete Response Letter from the FDA indicating that the BLA application did not meet the required evidence for effectiveness and highlighted the need for additional data. Following this announcement on July 11, 2025, Capricor's stock plummeted from $11.40 to $7.64 per share. This drastic decline underlines the significance of the information surrounding the class action.
The Gross Law Firm's Commitment
WHY CHOOSE THE GROSS LAW FIRM? The Gross Law Firm is recognized nationally in the realm of class action litigation. Its commitment is to advocate fervently for investors who have borne losses due to deceptive statements and practices. The firm fights vigorously to ensure that companies uphold ethical business standards and exercise responsibility.
Next Steps for Investors
As a shareholder in CAPR, registering your details is a crucial step in safeguarding your rights. Once you sign up, you’ll benefit from monitoring throughout the case's progress without incurring any fees. Be mindful of the pressing registration deadline; September 15, 2025, is the last day to express your interest in being a lead plaintiff.
Contact Information for Inquiries
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What is the class action regarding?
The class action involves allegations of misleading statements made by Capricor Therapeutics about their lead therapy candidate, deramiocel.
What should I do as a shareholder of CAPR?
If you purchased shares during the specified class period, it’s important to register your information to protect your rights.
Is there a cost to participate in the class action?
No, participation in the class action is free and carries no obligations.
What is the deadline to register?
The deadline to register for the class action is September 15, 2025.
Why should I contact The Gross Law Firm?
The Gross Law Firm specializes in representing investors in class action cases, offering expertise and a strong commitment to investor rights.
